Acasti Pharma Announces the Issuance of Additional Patents for GTX-104 and GTX-101

LAVAL, Québec, June 14, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that three composition of matter patents for GTX-104 were issued by The United States Patent and Trademark Office, the Japanese Patent Office, and the Australian Patent Office. Additionally, one new patent for GTX-104 was awarded by the Indian Patent Office. These granted patents are all valid until 2037.

NewsGuest UserJune 20, 2022BIOOQuébecGTX-104, GTX-101, Acasti Pharma

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

Acasti Pharma Inc. today provided a business update and announced that the Nasdaq Stock Market (“Nasdaq”) has confirmed to Acasti that the Company has regained compliance with Nasdaq’s minimum bid price requirement.

NewsGuest UserSeptember 23, 2021Acasti Pharma, Pharma